natgillin/translations-raw huggingface dataset:
Dosage form according to any of claims 1 to 10 for use in the prophylaxis or treatment of a clinical conidition in a mammal, wherein the clinical condition is selected from the group of benign gastric ulcer, gastro-oesophageal reflux disease, Zollinger-Ellison syndrome, duodenal ulcer, duodenal ulcer associated with Helicobacter pylori, prophylaxis of NSAID-associated gastric or duodenal ulcer in patients with an increased risk of gastroduodenal complication who require continued NSAID treatment and combination therapy with antibiotics in the eradication of Helicobacter pylori. 
Uporaba prema zahtjevu 8, naznačena time, da je kliničko stanje odabrano iz skupine koju čine: benigni gastrični ulkus, bolest gastrofagealnog refluksa, Zollinger-Ellison-sindrom, duodenalni ulkus, duodenalni ulkus povezan s bakterijom Helicobacter pylori, profilaksa za gastrični ili duodenalni ulkus povezan s NSAID kod pacijenata s povećanim rizikom za gastroduodenalne komplikacije koje zahtijevaju sustavno NSAID liječenje i kombinacijsku terapiju s antibioticima za eradikaciju bakterije Heliobacter pylori.
The resulting mixture was acidified with 10% HC1 and extracted with ethyl acetate (3 X 1 1. 
Dobivena smjesa se zakiseli sa 10% HCI i ekstrahira se sa etilacetatom (3x1 1.).
K i =IC 50/(1 +[L]/K D) where [L] is the concentration of a Radio-RUP25 Ligand used in the assay and KD is the dissociation constant of a Radio-RUP25 Ligand determined independently under the same binding conditions. 
K; = IC: / (1 + [L1/Kp) gdje je [L] koncentraija Radiološki označenog RUP25 liganda korištenog u ispitivanju i K, je konstanta disocijacije Radiološki označenog RUP25 liganda određena neovisno od samih uvjeta ispitivanja.
To achieve this goal, IL18-BP may be linked e.g. to Polyethlyenglycol (PEG). 
Kako bi se postigao ovaj cilj, IL-18BP može biti vezan za primjerice polietilenglikol (PEG).
Another embodiment of the invention is characterized in: 
Broj objave europskog patenta:
A compound or pharmaceutically acceptable salt according to any one of claims 1 and 2 for use in the treatment of irritable bowel syndrome. 
Spoj za uporabu sukladno patentnom zahtjevu 11, naznačeno time, da je bolest bol povezana sa sindromom iritabilnog crijeva.
Further concentration in vacuo gave pure 1,4,5,6-tetrahydrocyclopentapyrazole-3-carboxylic acid ethyl ester (63.6 g, 0.3 mol, 71 % yield) as a yellow solid. 
Daljnje koncentriranje in vacuo daje čisti etil ester 1,4,5,6-tetrahidrociklopentapirazol-3-karboksilne kiseline (63.6 g, 0.35 mol, 71% prinosa) kao žutu krutinu.
For the first embodiment, which is illustrated in FIGS. 1, 2 a, 2 b and 3, the nozzle 5 is shown in the section of FIG. 
Za prvu izvedbu, koja je prikazana na slikama 1, 2a, 2b i 3, mlaznica 5 je prikazana u presjeku na slici 2.
at least one inorganic acid ammonium salt. BRIEF DESCRIPTION OF THE DRAWING FIG. 
barem jednu amonijevu sol anorganske kiseline izabranu u skupini koju čine amonijevi sulfati i amonijevi fosfati.
▪ R9 represents two substituents selected from a methoxy group and a chlorine atom; and R10 represents a hydrogen atom. 
"Ro predstavlja dva supstituenta izabrana od metoksi skupine i klorovog atoma; i Ry predstavlja vodikov atom.
Most preferably, it is used as an additive in beverages bottled in green or clear glass. 
Najpoželjnije, upotrebljava se kao aditiv u pićima flaširanim u zelenom ili prozirnom staklu.
the antibody is for administration in combination with a therapeutically effective amount of at least one drug (a) selected from the group consisting of: anti-IgE antibody, antihistamine, bronchodilator, glucocorticoid, NSAID, decongestant, cough suppressant, analgesic, TNF-antagonist, integrin antagonist, immunosuppressive agent, IL-4 antagonist, IL-13 antagonist, dual IL-4/IL-13 antagonist, DMARD, antibody that binds to a B-cell surface marker and BAFF antagonist, or (b) which is an anti-IgE antibody, wherein the anti-IgE antibody is rhuMAbE25; and/or 
je protutijelo za primjenu u kombinaciji s terapeutski djelotvornom količinom barem jednog lijeka odabranog iz skupine koju čine: protutijelo anti-IgE, antihistamin, bronhodilator, glukokortikoid, NSAID, dekongestant, sredstvo za obuzdavanje kašlja, analgetik, TNF-antagonist, integrinski antagonist, imunosupresivno sredstvo, IL-4-antagonist, IL-13-antagonist, dvojni IL-4/IL-13-antagonist, DMARD, protutijelo koje se veže na površinski marker B-stanice i BAFF-antagonist; i/ili
3 and the amino acid sequence for the variable region of the light chain represented by SEQ ID NO. 
1 ili 3; i/ili varijabilno područje lakog lanca prikazano u SEQ ID NO.
Locomotor activity test, immediately after the simplified Irwin test Rotarod test, immediately after the locomotor activity test 
- Test lokomotornog djelovanja, neposredno nakon pojednostavljenog Irwin testa - Rotarod test, neposredno nakon testa lokomotornog djelovanja
reductive amination of the compound of formula 10 and a compound of formula 11: 
(b) reduktivne aminacije spoja formule 10 i spoja formule 11: NH
In this case when the line parts are opened these can remain attached to the chill chamber, for example because they are joined to one another via a hinge construction. 
U ovom slučaju, kad se dijelovi cijevi otvor, mogu ostati pričvršćene na hladnu komoru, na primjer zato jer su spojene jedna na drugu pomoću konstrukcije šarki.
The pharmaceutical composition of claim 2, wherein the composition comprises a B2 adrenergic receptor agonist and a steroidal anti-inflammatory agent. 
Farmaceutski pripravak iz Patentnog zahtjeva 19, naznačen time, da taj pripravak sadrži agonist 3, adrenergičkih receptora i steroidno protuupalno sredstvo.
The pharmaceutical composition according to Embodiment 2, wherein the pharmaceutical composition further contains a buffer. 
Farmaceutski sastav prema zahtjevu 1, pri čemu farmaceutski sastav dalje sadrži pufer.
Example 13: Crystallization of donepezil hydrochloride polymorph I kg of donepezil hydrochloride were suspended in 62 1 of methanol and 1.6 1 of water and heated to 60-65 °C to get a clear solution. 
Primjer 13: Kristalizacija donepezil hidroklorid polimorfa I 10,2 kg donepezil hidroklorida suspendirano je u 62 L metanola 1 1,6 L vode i zagrijano do 60-65 *C s ciljem dobivanja bistre otopine.
An installation according to claim 1, wherein the pump is double acting. 
Instalacija prema zahtjevu 1, naznačena time što je crpka (6) dvostruko djelujuća.
A method for treating a disease or condition selected from the group consisting of an inflammatory disorder, an allergic disorder, an autoimmune disease, and a cancer in a subject in need thereof, comprising administering to the subject a therapeutic effective amount of a compound of any of items 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14, or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers or tautomer thereof, or a pharmaceutical composition of item 15. 
Spoj sukladno bilo kojem od patentnih zahtjeva 1 do 5, ili njegova farmaceutski prihvatljiva sol, farmaceutski prihvatljiv kokristal, stereoizomer, mješavina stereoizomera ili tautomer, ili farmaceutski pripravak sukladno patentnom zahtjevu 6 za uporabu u postupku liječenja bolesti ili stanja odabranog iz skupine sastavljene od inflamatornog poremećaja, alergijskog poremećaja, autoimune bolesti i karcinoma.
The assembly of claim 19, wherein the chamber contains multiple doses of a component. 
Sklop prema patentnom zahtjevu 19, naznačen time, da komorica (20) sadrži više doza sastojka, kao što je cjepivo protiv gripe. t>&
an IL-15 polypeptide, wherein the IL-15 polypeptide comprises at least one amino acid substitution at one or more positions corresponding to position(s) 92, 93, 94, 95, 96, 97, 98, 99, 100, 112, 113, 114, 115 and/or 116 of the amino acid sequence shown in SEQ ID NO:1, thereby having a reduced affinity for interleukin 15 receptor, alpha subunit (IL-15Ra) compared to the affinity of wild-type IL-15 of SEQ ID NO: 1 (Uniprot number: P40933-1). 
polipeptid IL-15, gdje polipeptid IL-15 sadrži najmanje jednu aminokiselinsku zamjenu na jednom ili više položaja koji odgovaraju jednom ili više položaja 92, 93, 94, 95, 96, 97, 98, 99, 100, 112, 113, 114, 115 i/ili 116 u aminokiselinskom slijedu prikazanom u SEQ ID NO:1 pri čemu ima smanjeni afinitet za IL-15Ra u usporedbi s afinitetom divljeg tipa IL-15 sa SEQ ID NO: 1 (Uniprot broj: P40933-1), gdje se polipeptid IL-15 veže na IL-2/IL-15RBY, gdje se vežući protein bira iz skupine koju čine protutijelo, dvovalentni fragment protutijela, jednovalentni fragment protutijela ili proteinski vežuća molekula sa svojstvima vezanja kao kod protutijela.
A pharmaceutical composition according to clause 9, wherein lubricant is one or more selected from the group comprising magnesium, aluminium, zinc or calcium stearate, sodium stearyl fumarate, polyethylene glycol, mineral oil, stearic acid, hydrogenated vegetable oil, glyceryl behenate, glyceryl palmitostearate, glyceryl stearate, cornstarch, talc, calcium silicate, magnesium silicate, colloidal silicon dioxide, silicon hydrogel, and mixtures thereof. 
Oralni farmaceutski pripravak s kontroliranim oslobađanjem u skladu sa zahtjevom 8, naznačen time da je sredstvo za podmazivanje jedno ili više njih, odabranih između magnezijevog, aluminijevog, cinkovog ili kalcijevog stearata, natrij stearil fumarata, polietilen glikola, mineralnog ulja, stearinske kiseline, hidrogeniziranog biljnog ulja, gliceril behenata, gliceril palmitostearata, gliceril stearata, kukuruznog škroba, talka, kalcijevog silikata, magnezijevog silikata, koloidnog silicijevog dioksida, silicijevog hidrogela ili mješavina istih.
220-300 mg of concentrated r-hIL-18BP obtained from capture step reported above under (1) were thawed and adjusted to pH to 8.5±0.1, conductivity 50±5 mS/cm by adding few drops of 35% ortho-phosphoric acid (H3PO4) and solid NaCl in the amount corresponding to about 0.35M. 
HR P20070196 T3 220-300 mg koncentriranog r-hIL-18BP koji je dobiven u koraku lovljenja opisan ranije (1) bilo je otopljen i bio mu je podešen pH na 8.5 + 0.1, provodljivost na 50+5 mS/cm dodavanjem nekoliko kapi 35% orto-fosforne kiseline (H3POx) i krutog NaCI u količini koja odgovara 0.35 M.
The pharmaceutical composition of any one of items 67-69, further comprising a cytokine selected from the group consisting of IL-2, IL-3, IL-6, IL-11, IL-12, IL7, IL15, IL21, granulocyte macrophage colony stimulating factor, alpha, beta or gamma interferon and erythropoietin. 
Farmaceutski pripravak namijenjen upotrebi u liječenju neoplazije prema zahtjevu 20, te navedeni pripravak nadalje sadrži citokin odabran 1z skupine koju čine IL-2, IL -3, IL -6, IL -11, IL-12, IL-7, IL -15, IL-21, faktor stimulacije kolonija granulocita i makrofaga, alfa, beta ili gama interferon i eritropoetin.
The single molecule DNA-targeting RNA, or the nucleic acid comprising the nucleotide sequence encoding said single molecule DNA-targeting RNA, of claim 18, wherein the single molecule DNA-targeting RNA comprises one or more segments at the 5′ end of the targeter-RNA. 
RNK jednostruke molekule koja cilja na DNK, ili nukleinska kiselina koja obuhvaća nukleotidnu sekvencu koja kodira navedenu RNK jednostruke molekule koja cilja na DNK, pri čemu RNK jednostruke molekule koja cilja na DNK, obuhvaća sljedeće:
or a pharmaceutically acceptable salt thereof, comprising the steps of: reacting compound 6a: 
Spoj formule: nE ili njegova farmaceutski prihvatljiva sol za uporabu u liječenju gripe.
However, the method for preparing compound (16), or salt thereof, differs from method 5. 
54. Postupak za proizvodnju spoja u skladu sa sljedećom formulom (16) ili njegove soli:
transmitting a response signal that indicates error detection results of the received downlink data on an uplink subframe defined by the reference UL/DL configuration. 
signal odgovora nadalje označava rezultat otkrivanja pogrešaka podataka silazne veze primljenih na trećem nosaču komponenti.
The compound of clause 37, wherein the compound is selected from the group consisting of: 
Spoj prema zahtjevu 1, pri čemu je spoj odabran od skupine koja se sastoji od:
The pharmaceutical composition of claim 8 wherein the inhibitor of NS5B polymerase is a nucleotide inhibitor. 
Farmaceutski sastav patentnog zahtjeva 8, gdje je inhibitor NS5B polimeraze nukleotidni inhibitor. sena mnE
This wall element 2 forms the core of the building wall and is formed of a lightweight, heat insulating and preferably fire retarding, non-shrinking and stabile material in order to give the proper quality to the building wall. 
Ovaj zidni element 2 čini jezgru zida građevine, a izrađen je od laganog, toplinski izolirajućeg materijala po mogućnosti koji usporava gorenje, ne skuplja se i stabilan je, kako bi zidu građevine pružio odgovarajuću kvalitetu.
A coating composition comprising a co-processed microfibrillated cellulose and inorganic particulate material composition, wherein the microfibrillated cellulose has a fibre steepness of from 20 to 50. 
Artikl, naznačen time što sadrži: papirni proizvod, koji sadrži suobrađenu mješavinu mikrofibrilirane celuloze i anorganskog partikuliranog materijala; i
Semisolid mucoadhesive formulation, characterized in that it comprises: 
PATENTNI ZAHTJEVI Polučvrsta mukoadhezivna formulacija, naznačena time što sadrži:
Compounds of formula (Va): 
Spojevi formule (Va): am
A pharmaceutical composition comprising a therapeutically effective amount of a compound or pharmaceutically acceptable salt thereof according to claim 7 together with a pharmaceutically accepted carrier or excipient. 
ili njihova farmaceutski prihvatljiva sol. Farmaceutski sastav, naznačen time, da obuhvaća terapeutski učinkovitu količinu spoja prema zahtjevu 27, zajedno s farmaceutski prikladnim nosačem ili pomoćnim sredstvom.
Alternatively, suitably substituted 4-amino benzoic acids were coupled with suitably substituted 2-amino thiazoles in the presence of a carbodiimide coupling reagent such as 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride in the presence of a suitable additive such as 1-hydroxybenzotriazole in a suitable solvent such as 1,2-dichloroethane in the presence of a suitable base such as DIPEA, at a suitable temperature between 20-60 °C. 
Alternativno, prikladno supstituirane 4-amino benzojeve kiseline se spajaju s prikladno supstituiranima 2-amino tiazolima u prisutnosti karbodiimidnog sredstva za vezanje poput 1-(3-dimetilaminopropil)-3-etilkarbodiimid klorovodika u prisutnosti prikladnog aditiva poput 1-hidroksibenzotriazola u prikladnom otapalu kao što je 1,2-dikloroetan u prisutnosti prikladne baze poput DIPEA, na odgovarajućoj temperaturi između 20-60 "C.
A composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and component (B1) is azoxystrobin. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, le kao komponentu (B) ciprodinil.
The compound of claim 2 having the formula Id1: or a pharmaceutically acceptable tautomer, salt, or stereoisomer thereof. 
RK RENO 2 >NH O (Idl) ili njegov farmaceutski prihvatljiv tautomer, sol ili stereoizomer.
to 30% by weight, preferably 10 to 25% by weight, 
0 do 25% po težini sekundarne faze
94% (no change) 67% (1 grade improvement) 
94% (bez promjene) 67% (poboljšanje 1. stupnja)
The compound according to any one of claims 1 to 9, or the pharmaceutically acceptable salt thereof or the solvate thereof, wherein B1 is NR7a, and B2 is CR5aR6a, R5a is hydrogen, R6a is hydrogen, or lower alkyl optionally substituted by substituent group C, and R7a is lower alkyl optionally substituted by substituent group C, carbocyclic group optionally substituted by substituent group C, carbocycleoxy lower alkyl optionally substituted by substituent group C, heterocyclic group optionally substituted by substituent group C, carbocycle lower alkyl optionally substituted by substituent group C, heterocycle lower alkyl optionally substituted by substituent group C, or Z-C(RD7)(RD8)(RD9) (substituent group C, RD7, RC8, RD9, and Z are same as those of claim 1). 
aje vodik, ili niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, i a je niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, karbociklička skupina prema potrebi supstituirana sa supstituentskom skupinom C, karbocikliloksi niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, heterociklička skupina prema potrebi supstituirana sa supstituentskom skupinom C, karbociklil-niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, heterociklil-niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, ili Z-C(RD7)(RD8)(RD9), (dok supstituentska skupina C, RD7, RD8, RD9, i Z, imaju isto značenje kao što su navedeni u zahtjevu 1).
or a pharmaceutically acceptable salt thereof. The method of claim 2, wherein the compound has formula (VII) 
R R (VI), ili njegova farmaceutski prihvatljiva sol; ili formulu (VII)
One skilled in the art will recognize that HPLC is not an economical purification method for large-scale preparation of chemical compounds and difficulties associated with high volume purification may discourage the use of HPLC. 
Stručnjak ovog područja će znati kako HPLC nije ckonomična mctoda pročišćavanja za pripremu kemijskih spojeva u velikim razmjerima, a poteškoće vezane uz pročišćavanje velikih volumena mogu odvratiti od uporabe HPLC-a.
A method for producing a protein molecule composition, comprising introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding at least a part of said protein; and 
(a) uvođenju u stanicu domaćina, koja je imortalizirana stanica iz ljudske krvi podrijetlom iz ljudske mijeloidne leukemije, najmanje jedne nukleinske kiselina koja kodira u najmanju ruku dio navedenog protutijela; i
is a straight or branched C1-C9 alkyl, substituted with a group of the general formula (V): wherein each of R', R" and R"' is independently selected from a group consisting of straight or branched C1-C9 alkyl, straight or branched C1-C9 alkenyl and straight or branched C1-C9 alkynyl; 
HR P20190927 T1 PATENTNI ZAHTJEVI nos Spoj opće formule (IV): pri čemu je svaki RI-R8 neovisno odabran iz skupine koja sadrži H, OH, SH, halogen, nitro, amino, nitrilo, nitrozo, acetil, acetamid, aciklamid, alkilamin, ravan ili razgranati C1- C5 alkil, ravan ili razgranati C1-C5
Composition, medicament or pharmaceutical composition for use according to any one of claims 1 to 9, wherein said subject does not respond adequately to, or is unlikely to respond adequately to, one or more therapeutic agents in the group of corticoids, anti-TNF, anti-interleukins, anti-B lymphocytes, anti-costimulatory molecules, tolerogenic agents, anti-complement proteins, inhibitors of T cell signalling molecules, inhibitors of cell migration, methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, azathioprine, cyclosporine, minocycline, D-penicillamine. 
Smjesa, lijek ili farmaceutski pripravak za upotrebu prema bilo kojem zahtjevu od 1 do 8, naznačeni time da potrebiti pacijenti ne reagiraju adekvatno ili je mala vjerojatnost da će reagirati adekvatno na davanje jednog ili više terapijskih sredstava (agensa) iz skupine kortikoida, anti-TNF lijekova, anti-interleukina, protutijela za B-limfocite, anti-kostimulirajućih molekula, tolerogenih agensa, protutijela za proteine komplement sustava, inhibitora signalnih molekula za T-limfocite, inhibitora migracija stanica, metrotreksata, leflunomida, sulfasalazina, hidroksiklorokina, azatriopina, ciklosporina, minociklina i D-penicilamina.
A method of treating cancer selected from the group consisting of colorectal cancer, breast cancer, lung cancer, prostate cancer, glioblastoma, mantel cell lymphoma, chronic myeloid leukaemia and acute myeloid leukaemia in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of formula (I): 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 12, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju raka kojeg se bira iz skupine koju čine rak debelog crijeva, rak dojke, rak pluća, rak prostate, glioblastom, limfom stanica plašta, kronična mijeloidna leukemija i akutna mijeloidna leukemija.
The unit dose of claim 9 or 10, wherein the volume of the unit dose is 2 mL, 3 mL, 4 mL or 5 mL. 
Jedinična doza iz zahtjeva 9 ili 10, pri čemu je volumen jedinične doze 2, 3, 4 ili 5 mL.
The compound according to claim lor 2 or a salt thereof, or a solvate of the compound or the salt, wherein Rb is optionally C1-4 alkoxy-substituted C1-5 alkoxy or a halogen atom; 
Spoj prema patentnom zahtjevu 1 ili 2, ili njegova sol, ili solvat spoja ili sol, naznačen time što Rb je po izboru C1-4 alkoksi-supstituiran C1-5 alkoksi ili halogeni atom;
Purification on a silica gel column (methanol:dichloromethane, 4:1 and 3:1) provided the product as white foam 2.70 g (81%). 
Pročišćavanje na koloni silikagela (metanol:diklorometan 4:1 i 3:1) dalo je produkt kao bijelu pjenu, 2,70 g (81%).
Preferred alkynyl groups have 2 to 12 carbon atoms in the chain; and more preferably 2 to 4 carbon atoms in the chain. 
Poželjne alkinilne skupine imaju 2 do 12 ugljikovih atoma u lancu; poželjnije 2 do 4 ugljikova atoma u lancu.
is selected from the group consisting of —COOR10 wherein 
R, je izabran iz grupe koja se sastoji od -COORi9 gdje
treating the compound of formula (5), or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof, with an aldehyde under suitable conditions to form a compound of formula (6): or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof; 
HO S N ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese; obradi spoja formule (5), ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese, aldehidom u uvjetima pogodnim za dobivanje spoja formule (6):
The method of claim 1, wherein the one or more size dimensions are length, width, height, or diameter. 
Postupak prema zahtjevu 1, naznačen time što su jedna 1li više dimenzija veličine duljina, širina, visina ili promjer.
The upper part of the floor element 18 is smaller and has a trapezoid cross section. 
Gornji dio podnog elementa 18 je manji i ima presjek trapeznog oblika.